Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Common Equity (2019 - 2025)

Historic Common Equity for Avidity Biosciences (RNA) over the last 7 years, with Q3 2025 value amounting to $1.9 billion.

  • Avidity Biosciences' Common Equity rose 2546.83% to $1.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 billion, marking a year-over-year increase of 2546.83%. This contributed to the annual value of $1.4 billion for FY2024, which is 18455.7% up from last year.
  • Latest data reveals that Avidity Biosciences reported Common Equity of $1.9 billion as of Q3 2025, which was up 2546.83% from $1.2 billion recorded in Q2 2025.
  • Over the past 5 years, Avidity Biosciences' Common Equity peaked at $1.9 billion during Q3 2025, and registered a low of $264.5 million during Q2 2021.
  • Moreover, its 5-year median value for Common Equity was $558.9 million (2023), whereas its average is $766.1 million.
  • As far as peak fluctuations go, Avidity Biosciences' Common Equity tumbled by 1992.64% in 2021, and later surged by 19052.62% in 2024.
  • Avidity Biosciences' Common Equity (Quarter) stood at $381.4 million in 2021, then soared by 51.55% to $578.1 million in 2022, then decreased by 13.37% to $500.8 million in 2023, then skyrocketed by 184.56% to $1.4 billion in 2024, then skyrocketed by 32.37% to $1.9 billion in 2025.
  • Its Common Equity was $1.9 billion in Q3 2025, compared to $1.2 billion in Q2 2025 and $1.3 billion in Q1 2025.